Market Intelligence Center  2 hrs ago  Comment 
The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered-call trade on Sanofi-Aventis (SNY) that includes 3.87% downside protection. Sell one contract of the Jun....
The Hindu Business Line  Feb 24  Comment 
Jubilant Life Sciences has received approval from the US regulator for Irbesartan and Cetirizine Hydrochloride tablets used for treatment of hypertension and allergies respectively. It has receive...
Motley Fool  Feb 24  Comment 
Sanofi's new CEO Olivier Brandicourt will have an impact on the success of MannKind's Afrezza.
FiercePharma  Feb 23  Comment 
Olivier Brandicourt has been Sanofi's official CEO pick for just 4 days, and already he's in the midst of a controversy. It's all about his pay package, which is generous in European terms, but not unusual in the ranks of global pharma executives.
Market Intelligence Center  Feb 23  Comment 
After closing Friday at $50.10, Sanofi-Aventis (SNY) presents an attractive opportunity to get a 3.95% return in just 116 days, which is an annualized return of 12.43% (for comparison purposes only). To enter this trade, sell one Jun. '15 $50.00...
Clusterstock  Feb 23  Comment 
PARIS (Reuters) - French pharmaceuticals group Sanofi came under fire from French government ministers on Monday over a welcome bonus planned for its new CEO. Sanofi's new boss, Olivier Brandicourt could pocket a one-off golden handshake of 4...
FierceBiotech  Feb 22  Comment 
Regeneron and its close partner Sanofi have posted another set of promising results for dupilumab--which targets the interleukin-4 and interleukin-13 inflammatory proteins--from a Phase IIb study that backs up those high expectations.
Wall Street Journal  Feb 20  Comment 
Sanofi has found a credible, new chief executive who just happens to be French. But the boss has a daunting task ahead on his arrival.
Wall Street Journal  Feb 20  Comment 
Sanofi named pharmaceutical veteran Olivier Brandicourt its new CEO, as it faces stiff competition and prepares to launch new products.
FierceBiotech  Feb 20  Comment 


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki